Stock market strategist Thomas Lee says there's plenty of proof the bull market still has several years to go.» Read More
NEW YORK— Merck is licensing an experimental psoriasis drug to Indian drugmaker Sun Pharmaceuticals, the companies said Wednesday. The Whitehouse Station, New Jersey, company will also get royalties on sales if the drug is approved. Shares of Merck& Co. slipped 41 cents to $59.58 in morning trading.
*Lilly to partner on AstraZeneca's BACE inhibitor drug. LONDON, Sept 16- AstraZeneca has signed a partnership deal with U.S. rival Eli Lilly that could earn the British company up to $500 million if a promising- but risky- experimental Alzheimer's drug proves successful.
Sept 15- Merck& Co said it will seek U.S. approval next year for its long-delayed experimental osteoporosis drug, odanacatib, after it proved effective in a late-stage trial but was associated with rare thigh-bone fractures seen with standard treatments.
Sept 15- Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.
JOHANNESBURG, Sept 10- Aspen Pharmacare is to sell the rights to market a blood clot drug in the United States to rival Mylan Inc for up to $300 million, it said on Wednesday, a move that would help Africa's top generic drugmaker pay down debt.
TRENTON, N.J.— Merck& Co. on Thursday won the first U.S. approval for a new kind of cancer drug with big advantages over chemotherapy and other older cancer treatments.
U.S. stocks closed mixed on Wednesday, coming off morning highs amid economic reports and central bank news.
*Zoetis explores international markets for product. CHICAGO, Sept 3- Zoetis Inc has received a conditional license from the U.S. Department of Agriculture for its vaccine against a deadly piglet virus and will begin selling it this month in the United States, the company said on Wednesday.
CHICAGO, Sept 3- Zoetis Inc, the world's largest animal-health company, has received a conditional license from the U.S. Agriculture Department for its vaccine against a deadly piglet virus and will begin selling it this month in the United States, the company said on Wednesday.
As tensions between Hong Kong and Beijing increase, multinational firms are seeing more stability in Singapore and expanding their outlook.
*AstraZeneca shares up 2 percent. LONDON, Aug 29- Hopes for AstraZeneca's promising cancer drug pipeline were boosted on Friday by news the company had moved its immuno-oncology medicine MEDI-4736 into a mid-stage study in colorectal cancer.
Some of the names on the move ahead of the open.
The "Fast Money" traders share their final trades of the day.
Some of Tuesday's midday movers:
Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.
Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in the hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.
What have we learnt from the recent reporting flurry? Societe Generale has put together a list of conclusions to be drawn from this earnings season.
Bankers and lawyers providing takeover advice said on Monday that Burger King Worldwide Inc's intention to move its tax domicile overseas through a so-called inversion deal- in this case the purchase of Canada's Tim Hortons- shouldn't be seen as a sign of a lot more deals to come.
Some of Monday's midday movers:
Roche's deal for InterMune is one of the few this year that returns to the traditional model of big pharma buying smaller biotech.